## NEXT STEPS TO GETTING STARTED ON GATTEX

# The Takeda Patient Support Program offers personalized assistance throughout your treatment journey

Now that you've decided to start treatment with GATTEX, completed the Start Form, and elected to enroll in the Takeda Patient Support Program, please refer to the checklist below to see what you can expect next.

Your Takeda Patient Support team includes your dedicated **Patient Support Manager (PSM)**. Upon enrollment, your PSM will call you to:

- Explain Takeda Patient Support services and obtain your consent
- Confirm the information on your Start Form, including insurance benefits and coverage

*Your PSM welcome call may last around 30 minutes.* **Please be sure to have your insurance information available.** 

## Your PSM (Name, Phone) \_

Your Takeda Patient Support team also includes your **Onboarding & Access Specialist (OAS)**. Your OAS will set up a meeting to help you get started with treatment and answer any questions related to:

- Insurance and financial assistance options
- GATTEX and potential side effects
- Next steps in your treatment journey

## Your OAS (Name, Phone)

Once your insurance company approves your GATTEX prescription, it will be sent to you by a **specialty pharmacy** (a mail-order pharmacy that provides specialty medications)

• Your specialty pharmacy will reach out to confirm delivery and can also guide and support you in administering your treatment

A **Nurse Educator** (ie, GATTEX Injection Training Nurse) will come to your home and train you on how to administer GATTEX according to the Instructions for Use

- The Nurse Educator can meet with you up to 4 times to ensure that you know how to administer GATTEX
- Please contact your OAS or PSM for ongoing support

**Note:** Depending on your insurance, the timeline for starting GATTEX can vary. To avoid delays, **please be sure to answer calls** from your Takeda Patient Support team, specialty pharmacy, and Nurse Educator, which may come from unknown numbers.

Call Takeda Patient Support at **1-866-888-0660**, Monday through Friday, 8:30 AM to 8:00 PM eastern time, or visit <u>gattex.com/getting-started</u> to learn more.

Please discuss any questions with your doctor.





#### BOTH PATIENT AND PRESCRIBER SIGNATURES ARE REQUIRED TO AUTHORIZE THIS FORM.

Takeda Patient Support Start Form: Authorization for Services Available for patients 1 year of age and older



FAX PAGE 1 OF THIS FORM TO: 1-855-359-3393 PHONE: 1-866-888-0660

Π	1. PATIENT INFORMATION		
L	Full Name	Caregiver (First, Last)	
	DOB (MM/DD/YYYY) Male Female	Relationship to Patient	Phone
	Last 4 Digits of SSN Email	providers other than the GATTEX prescribing physician), I am authorizing any	
IEN	Address	employees of the Companies to follow up with these Care Team Members to provide education and information about GATTEX.	
PAT	City/State/ZIP		
JΒγ	Primary Phone Secondary Phone	Care Team Role	
ETE	Special Precautions (eg, allergies)	Español es mi primer idioma	*Optional.
	I would like to opt in to marketing communications.		
<ul> <li>TO BE COMPLETED BY PATIENT</li> </ul>	Patient Authorization I have read, understand, and agree to the release of my protected health information, as described on Page 2, Section 6 of this form. X		
	Patient signature/legal representative signature (indicate relationship)		Date
	Takeda Patient Support Program and Communications Enrollment         I have read, understand, and agree to the use of my personal information for the purposes described on Page 2, Section 7 of this form.         X		
٦	Patient signature/legal representative signature (indicate relationship)		Date
Н	2. INSURANCE INFORMATION		
	REQUIRED: Include copies of both sides of the patient's medical and prescription insurance card(s) Check if the patient does not have insurance		
	Primary Insurance Insurance Phone	Secondary Insurance	Insurance Phone
	Policy ID # Group	Policy ID #	_ Group
	Policy Holder Name (First, Last)	Policy Holder Name (First, Last)	
	DOB (MM/DD/YYYY) Relationship to Patient	DOB (MM/DD/YYYY)	Relationship to Patient
	Pharmacy Plan Policy ID #	Group #	
	Pharmacy Plan Phone Rx Bin #	Rx PCN #	
	3. PRESCRIBING PHYSICIAN INFORMATION 4. PATIENT CLINICAL INFORMATION		
	Full Name Treatment Center	Diagnosis*	Etiology
	Full Name          Address	New Start	Inflammatory Bowel Disease (IBD)
IAN		New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition	
SICIAN	Address City/State/ZIP	New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support)	Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD
PHYSICIAN	Address           City/State/ZIP           Phone   Fax	New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support) Existing Patient GATTEX renewal	Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction],
ICE/PHYSICIAN	Address City/State/ZIP Phone Fax Treatment Center Name Office Contact Name	New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support) Existing Patient GATTEX renewal *Please do not check a box if neither applies.	Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event,
OFFICE/PHYSICIAN	Address	New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support) Existing Patient GATTEX renewal	Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, midgut volvulus])
BY OFFICE/PHYSICIAN	Address	New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support) Existing Patient GATTEX renewal *Please do not check a box if neither applies. Date of Last	Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis,
TED BY OFFICE/PHYSICIAN	Address	New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support) Existing Patient GATTEX renewal *Please do not check a box if neither applies. Date of Last Intestinal Resection	Inflammatory Bowel Disease (IBD)         (eg, chronic conditions such as Crohn's disease)         Non-IBD         (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, midgut volvulus])         Parenteral Support         Provider/Pharmacy
TO BE COMPLETED BY OFFICE/PHYSICIAN	Address	New Start         Short bowel syndrome (SBS) patient         dependent on parenteral nutrition         and/or IV fluids (parenteral support)         Existing Patient         GATTEX renewal         *Please do not check a box if neither applies.         Date of Last         Intestinal Resection         ICD-10 Code         e-specific prescription form, e-prescribing,         than 10 kg)         rment or end-stage         n²)	Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, midgut volvulus]) Parenteral Support Provider/Pharmacy etc. of 30-vial kits needed e than 3.8 mg/day, two 30-vial kits
TO BE COMPLETED BY OFFICE/PHYSICIAN	Address	New Start         Short bowel syndrome (SBS) patient         dependent on parenteral nutrition         and/or IV fluids (parenteral support)         Existing Patient         GATTEX renewal         *Please do not check a box if neither applies.         Date of Last         Intestinal Resection         ICD-10 Code         e-specific prescription form, e-prescribing,         STEP 2: Choose #         than 10 kg)         renet or end-stage	<ul> <li>Inflammatory Bowel Disease (IBD)         <ul> <li>(eg, chronic conditions such as Crohn's disease)</li> <li>Non-IBD</li></ul></li></ul>
TO BE COMPLETED BY OFFICE/PHYSICIAN	Address	New Start         Short bowel syndrome (SBS) patient         dependent on parenteral nutrition         and/or IV fluids (parenteral support)         Existing Patient         GATTEX renewal         "Please do not check a box if neither applies.         Date of Last         Intestinal Resection         ICD-10 Code         e-specific prescription form, e-prescribing,         step 2: Choose #         than 10 kg)         rment or end-stage         n?)         If dose is more         are recommed         mg/day)         One (1) 30-Vial         'A maximum of 0.3	Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease)         Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, midgut volvulus])         Parenteral Support         Provider/Pharmacy         etc.         of 30-vial kits needed         et than 3.8 mg/day, two 30-vial kits nded <sup>†</sup> Kit/NDC # 68875-0102-01/Vial Size: 5 mg 8 mL of the reconstituted solution, containing 3.8 mg of
TO BE COMPLETED BY OFFICE/PHYSICIAN	Address	New Start         Short bowel syndrome (SBS) patient         dependent on parenteral nutrition         and/or IV fluids (parenteral support)         Existing Patient         GATTEX renewal         *Please do not check a box if neither applies.         Date of Last         Intestinal Resection         ICD-10 Code         e-specific prescription form, e-prescribing,         than 10 kg)         rment or end-stage         n²)         If dose is more are recomment         mg/day)       One (1) 30-Vial         'Ya maximum of 0.3         tedudutide, can b	Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease)         Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, midgut volvulus])         Parenteral Support         Provider/Pharmacy         etc.         of 30-vial kits needed         Kit/NDC # 68875-0102-01/Vial Size: 5 mg         Kits/NDC # 68875-0102-01/Vial Size: 5 mg
TO BE COMPLETED BY OFFICE/PHYSICIAN	Address	New Start         Short bowel syndrome (SBS) patient         dependent on parenteral nutrition         and/or IV fluids (parenteral support)         Existing Patient         GATTEX renewal         "Please do not check a box if neither applies.         Date of Last         Intestinal Resection         ICD-10 Code         e-specific prescription form, e-prescribing,         than 10 kg)         rment or end-stage         n?)         If dose is more         are recommel         'Amaximum of 0.3         teduglutide, can be         'Amaximum of 0.3         teduglutide, can be	Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, midgut volvulus]) Parenteral Support Provider/Pharmacy etc. of 30-vial kits needed et than 3.8 mg/day, two 30-vial kits nded <sup>†</sup> Kit/NDC # 68875-0102-01/Vial Size: 5 mg Kits/NDC # 68875-0102-01/Vial Size: 5 mg mL of the reconstituted solution, containing 3.8 mg of e withdrawn from each vial for dosing.
TO BE COMPLETED BY OFFICE/PHYSICIAN	Address	New Start         Short bowel syndrome (SBS) patient         dependent on parenteral nutrition         and/or IV fluids (parenteral support)         Existing Patient         GATTEX renewal         "Please do not check a box if neither applies.         Date of Last         Intestinal Resection         ICD-10 Code         e-specific prescription form, e-prescribing,         than 10 kg)         rment or end-stage         n?)         If dose is more         are recommel         'Amaximum of 0.3         teduglutide, can be         'Amaximum of 0.3         teduglutide, can be	Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease)         Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, midgut volvulus])         Parenteral Support Provider/Pharmacy         etc. of 30-vial kits needed         et than 3.8 mg/day, two 30-vial kits nded <sup>†</sup> Kit/NDC # 68875-0102-01/Vial Size: 5 mg 8 mL of the reconstituted solution, containing 3.8 mg of e withdrawn from each vial for dosing.         /. Number of refills

## **Authorization for Takeda Patient Support**

PLEASE READ THROUGH THE LANGUAGE ON THIS PAGE BEFORE SIGNING THE AUTHORIZATION AND CONSENT IN SECTION 1 OF THE START FORM.

## 6. PATIENT AUTHORIZATION TO SHARE PROTECTED HEALTH INFORMATION

I authorize any health plan, physician, health care professional, hospital, clinic, pharmacy provider or other health care provider (collectively, "Providers") to disclose my protected health information, including personal information relating to my medical condition, treatment, care management, and health insurance, as well as all information provided on this form and any prescription ("Information"), to Takeda Pharmaceutical Company Limited, its affiliates and their representatives, agents, and contractors (collectively, the "Company" or "Takeda") in connection with the Company's provision of products, supplies, or services. I understand the Company will provide this Information to a specialty pharmacy to fulfill the prescription. This Information may also be used for internal uses by the Company, including data analysis. Further, I understand that my physician, health insurance, and pharmacy providers may receive financial remuneration from the Companies for providing Protected Health Information, which may be used for marketing purposes.

Further, the Company may use this Information for Takeda Patient Support Services ("Services") (if I agree on page 1) such as verification of insurance benefits and drug coverage, prior authorization support, financial assistance with co-pays, patient assistance programs, alternate funding sources, other related programs, communication with me or my prescribing physician by mail, email, or telephone about my medical condition, treatment, care management, product information and health insurance.

I understand that once disclosed to the Company, my Personal Health Information disclosed under this Authorization may no longer be protected by federal privacy law, including HIPAA. I understand that I am entitled to a copy of this Authorization. I understand that I may cancel this Authorization at any time by sending written notice of revocation to Takeda Patient Support, 300 Shire Way, Lexington, MA 02421. I understand that such revocation will not apply to any information already used or disclosed through this Authorization. This Authorization will expire within five (5) years from today's date, unless a shorter period is provided for by state law.

I understand that I may refuse to sign this Authorization and that refusing to sign this Authorization will not change the way my physician, health insurance, and pharmacy providers treat me. I also understand that if I do not sign this Authorization, I will not be able to receive Services from Takeda.

## 7. TAKEDA PATIENT SUPPORT ENROLLMENT

By signing the Takeda Patient Support Program and Communication Enrollment section on page 1, section 1, I am electing to enroll in the Services and direct all disclosures of my Information in connection with such Services (which may include, but is not limited to, verification of insurance benefits and drug coverage, prior authorization support, financial assistance with co-pays, patient assistance programs, alternate funding sources, other related programs, communication with me or my prescribing physician by mail, email, or telephone about my medical condition, treatment, care management, product information and health insurance).

## 8. PATIENT CONSENT FOR MARKETING COMMUNICATIONS

By checking the box on page 1, section 1, I authorize the use of my Information for Takeda marketing activities and consent to receiving marketing and promotional communications from Takeda. I hereby give consent to Takeda, its affiliates, and their agents and representatives to send communications and information to me via the contact information I have provided on page 1. I understand that this consent will be in effect until I cancel such authorization.

Page 2

## Please click here for full <u>Prescribing Information</u>.



